Merus

Biotech & Life Sciences · Utrecht, Netherlands · Founded 2003 · IPO 2016

Merus N.V. is a clinical-stage oncology company specializing in the development of innovative, full-length multispecific antibodies known as Biclonics®. These bispecific antibody therapeutics are engineered to harness the immune system to target and eliminate cancer cells, offering more effective treatments with fewer side effects. The company operates in the biotechnology sector, primarily serving patients battling cancer. Merus collaborates with other life sciences companies, such as Caris Life Sciences, to enhance patient identification and enrollment for clinical trials, including the Zenocutuzumab Phase 1/2 eNRGy trial. The business model focuses on research and development, clinical trials, and partnerships to bring their therapeutic solutions to market. Revenue is generated through collaborations, licensing agreements, and potential future sales of approved therapies. Keywords: oncology, bispecific antibodies, immune system, cancer treatment, clinical trials, biotechnology, Biclonics®, Zenocutuzumab, patient enrollment, therapeutic solutions.

Valuation $6.20B

Revenue $36M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Investors

8 investors on Merus's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage

EQT Life Sciences

Novartis Venture Fund

Bay City Capital

Pfizer

Aglaia BioMedical Ventures

Johnson & Johnson Development Corporation

Series B+ 2 investors entered at this stage

Sofinnova Partners

Novo Holdings

Global footprint

Where Merus has talent and traffic

Workforce by country

11 countries with
team presence

🇳🇱 Netherlands60.2%

🇺🇸 United States32%

🇬🇧 United Kingdom2.4%

🇨🇭 Switzerland1.5%

🇪🇸 Spain1%

Top 5 of 11 shown

Web traffic by country

9K monthly visits
across markets

🇺🇸 United States45.6%

🇮🇳 India21.1%

🇳🇱 Netherlands17.8%

🇯🇵 Japan12.2%

🇫🇷 France2.2%

Top 5 markets shown

Talent graph

The shape of Merus's talent

Dealroom maps Merus's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

8 standout operatorsDealroom-flagged across the org

2 AI specialistsincl. 2 core researchers

228 employees mappedperson by person

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Merus's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$170M patent portfolio · 101 active families

Estimated portfolio value

$170M

2.7% of market cap · 449.4× larger than top peer Y-mAbs Therapeutics ($378k)

101 active patent families

Where Merus innovates AntibodyAntiendomysial antibodiesBinding domainCancer researchCarcinosis

Where Merus concentrates vs peers

Each axis is a top-10 topic across Merus and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Merus

An AI-synthesized read of the highest-engagement posts about Merus on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Merus on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles